Amicus Therapeutics to Announce Third Quarter 2022 Financial Results on November 7, 2022
October 27, 2022 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, November 7, 2022 at...
Amicus Therapeutics Announces Participation at World Muscle Society 2022
October 11, 2022 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced four poster presentations highlighting its development program for Pompe disease will be included...
Amicus Therapeutics Announces Participation at the 2022 AANEM Annual Meeting
September 21, 2022 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced three poster presentations highlighting its development program for Pompe disease will be...
Amicus Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
September 08, 2022 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Morgan Stanley 20th Annual Global...
Amicus Therapeutics Announces Second Quarter 2022 Financial Results
August 04, 2022 07:00 ET
|
Amicus Therapeutics, Inc.
1H22 Galafold® Revenue of $159.4M, reflecting 11% Sales Growth with Operational Growth of 18%, Partly Offset by Currency Headwinds of 7% On-Track to Deliver Full-Year Double-Digit Revenue Growth of...
Amicus Therapeutics to Announce Second Quarter 2022 Financial Results on August 4, 2022
July 26, 2022 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, July 26, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, August 4, 2022 at...
Amicus Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
June 08, 2022 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, June 08, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Goldman Sachs 43rd Annual Global...
Amicus Therapeutics Receives Notification of PDUFA Date Extensions for AT-GAA
May 10, 2022 16:01 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, May 10, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period by 90 days for the...
CORRECTING AND REPLACING -- Amicus Therapeutics Announces First Quarter 2022 Financial Results
May 09, 2022 09:15 ET
|
Amicus Therapeutics, Inc.
1Q22 Galafold® Revenue Growth of 18.5% to $78.7M New Composition of Matter Patent for Galafold® Strengthens U.S. Patent Protection into 2038 Advancing U.S. and EU Regulatory Reviews and...
Amicus Therapeutics Announces First Quarter 2022 Financial Results
May 09, 2022 07:00 ET
|
Amicus Therapeutics, Inc.
1Q22 Galafold® Revenue Growth of 18.5% to $78.7M New Composition of Matter Patent for Galafold® Strengthens U.S. Patent Protection into 2038 ...